Beta Blockers for Anxiety: Performance Anxiety, Physical Symptoms, and Limits
Updated: Oct 8
Author: Ukrainian Psychological Hub · Published: October 1, 2026 · Editorial Policy
Beta blockers can reduce some of the body’s adrenergic signs of anxiety—especially a racing or pounding heart and tremor—and this is why medicines such as propranolol are sometimes prescribed off-label for brief, predictable performance situations. That narrow use is different from treating an anxiety disorder. The strongest recent systematic review found no robust evidence that beta blockers improve anxiety disorders such as social anxiety disorder or panic disorder compared with placebo or benzodiazepines, and the certainty of the evidence was very low. Archer et al. (2025)
The practical distinction is simple: beta blockers mainly change selected physical outputs of the stress response. They do not reliably remove fear of negative evaluation, persistent worry, catastrophic predictions, avoidance, safety behavior, or the learning processes that maintain many anxiety disorders. For some people, reducing visible or uncomfortable physical arousal can still be useful in a specific situation; for others, it changes little because the dominant problem is cognitive, behavioral, or diagnostic rather than autonomic.
This article explains what beta blockers can and cannot do for anxiety, why propranolol is the best-known example, how performance anxiety differs from performance-only social anxiety disorder, what current evidence actually shows, and why cardiovascular, respiratory, metabolic, and medication factors matter before use.
Quick answer: do beta blockers work for anxiety?
They can help some physical symptoms of short-lived anxiety, but they are not a general-purpose treatment for anxiety disorders. The U.S. National Institute of Mental Health notes that clinicians may prescribe beta blockers off-label for short-term anxiety symptoms and that they can help manage physical signs such as rapid heart rate, sweating, and tremor. NIMH Mental Health Medications
That does not mean the evidence is equally strong for every anxiety problem. In a 2025 systematic review and meta-analysis of 10 studies, five of which entered meta-analysis, beta blockers showed no evidence of benefit over placebo or benzodiazepines for social phobia or panic disorder with or without agoraphobia. The meta-analyzed sample was small, many studies had important risk-of-bias problems, and the overall certainty was very low. Archer et al. (2025)
A useful way to read the evidence is therefore: the pharmacologic effect on the body is established; the off-label clinical use for selected short-term performance situations is common and acknowledged by authoritative health sources; the evidence that beta blockers treat psychiatric anxiety disorders is weak; and the evidence base for performance anxiety itself is older and methodologically limited.
What are beta blockers?
Beta blockers, or beta-adrenergic blocking agents, are a class of medications that reduce the effects of catecholamines such as adrenaline and noradrenaline at beta receptors. They are used for several cardiovascular and other medical indications. Propranolol is a nonselective beta blocker, meaning that it blocks both beta-1 and beta-2 adrenergic receptors. Its official U.S. label describes reduced chronotropic and inotropic responses to beta-adrenergic stimulation—that is, reduced effects on heart rate and cardiac contraction. DailyMed propranolol label
Propranolol is the beta blocker most commonly discussed in relation to anxiety, but it should not be treated as interchangeable with every medication in the class. Beta blockers differ in receptor selectivity, lipid solubility, approved indications, pharmacokinetics, interaction profiles, and clinical safety considerations. Evidence involving propranolol cannot automatically be generalized to atenolol, metoprolol, nadolol, or other beta blockers.
Why beta blockers can change physical anxiety symptoms
Anxiety can activate autonomic and endocrine responses that increase heart rate, make the heartbeat feel more forceful, and intensify tremor. By blocking beta-adrenergic signaling, a beta blocker can blunt part of this physiological response. Propranolol’s official labeling also notes clinical benefit for exaggerated physiological and essential tremor, illustrating its peripheral antitremor action. DailyMed clinical pharmacology
For a person whose main performance problem is a visibly shaking hand, a pounding heart, or a voice destabilized by intense adrenergic arousal, dampening those sensations may reduce interference with the task. NIMH similarly describes beta blockers as helping control physical social-anxiety symptoms including rapid heart rate, sweating, and tremor. NIMH Social Anxiety Disorder
The effect is narrower than the phrase “anti-anxiety medication” can suggest. A medication can reduce heart rate without changing the prediction “everyone will notice I am failing.” It can reduce tremor without changing avoidance of presentations. It can reduce bodily feedback without changing chronic worry. That distinction explains both the clinical appeal of beta blockers in some performance contexts and their limitations as a treatment for anxiety disorders.
For a broader map of bodily symptoms—and why no single physical symptom establishes an anxiety diagnosis—see Physical Symptoms of Anxiety: Heart, Breathing, Stomach, Muscles, and Dizziness.
Performance anxiety is not one single diagnosis
“Performance anxiety” is a descriptive phrase. It can refer to ordinary nervousness before a meaningful event, a more impairing but situation-specific fear, or a clinical presentation within social anxiety disorder. These states overlap phenomenologically but do not have the same diagnostic meaning.
Normal performance nerves
A temporary increase in arousal before a speech, examination, interview, audition, competition, or performance can be an ordinary stress response. The person may feel activated, notice a faster heartbeat, or experience butterflies and still perform effectively. Normal anticipatory arousal is not converted into a disorder merely because it feels uncomfortable.
Performance anxiety as an informal clinical description
Some people experience recurrent, disproportionate distress in performance situations without a clear broader syndrome. The phrase can describe the problem, but assessment still asks what is feared, how often it occurs, whether situations are avoided, how much functioning is affected, and whether the pattern maps onto a recognized disorder.
Performance-only social anxiety disorder
Social anxiety disorder is defined by marked fear or anxiety in social situations involving possible scrutiny. In some people, the clinically significant fear is restricted to speaking or performing in public. NIMH explicitly notes this performance form and describes beta blockers as commonly used for its physical symptoms, while disorder-specific treatment guidance still gives major roles to cognitive behavioral therapy and, when medication is chosen for ongoing social anxiety disorder, antidepressants such as SSRIs. NIMH Social Anxiety Disorder
Our dedicated pages separate these intents: Performance-Only Social Anxiety Disorder: Public Speaking and Performance Fear explains the diagnostic territory, while Social Anxiety vs Performance Anxiety: Generalized Social Fear vs Specific Performance Fear compares the broader concepts.
What does the research show for performance anxiety?
The reputation of propranolol for stage fright is older than the modern evidence standards now applied to psychiatric treatment. A small double-blind study in professional musicians published in 1982 reported effects of beta blockade on stage fright, but only 29 people participated across two trials. Brantigan et al. (1982)
Later reviews have repeatedly emphasized the limitations of this literature. A 2019 systematic review of music performance anxiety found that beta blockers were among the treatments studied, but methodological quality across intervention research was uneven, with weaknesses in participant selection, control groups, blinding, randomization, confounding, and analysis. Fernholz et al. (2019)
A 2018 review focused on exam-related anxiety likewise concluded that evidence for both effectiveness and safety was sparse for that non-approved indication. Vinther et al. (2018)
This creates an important evidence distinction. It is plausible—and consistent with pharmacology—that beta blockade can reduce adrenergic performance symptoms. It is also clinically common for propranolol to be used this way. What is not established is that beta blockers broadly treat the psychological construct of performance anxiety, improve every kind of performance, or provide a durable treatment for the fear and avoidance that can surround repeated performances.
What does the evidence show for diagnosed anxiety disorders?
The evidence becomes less supportive when the question shifts from “Can this reduce physical arousal in a specific situation?” to “Does this treat an anxiety disorder?” The 2025 meta-analysis found no evidence of a beneficial effect of beta blockers compared with placebo or benzodiazepines in social phobia or panic disorder with or without agoraphobia. Its primary analyses were graded very low certainty because the evidence base was small, imprecise, and at risk of bias. Archer et al. (2025)
An earlier systematic review of propranolol reached a similar conclusion. It included eight studies covering panic disorder with or without agoraphobia, specific phobia, social phobia, and PTSD-related questions. The authors found insufficient evidence to support routine propranolol use for any anxiety disorder. Steenen et al. (2016)
Generalized anxiety disorder
Generalized anxiety disorder is characterized by persistent, excessive anxiety and worry across domains, accompanied by associated symptoms and impairment. A beta blocker may reduce a peripheral symptom such as tachycardia in some contexts, but it does not directly target the broad worry process that defines GAD, and current evidence does not establish beta blockers as a routine GAD treatment. For disorder-specific medication evidence, see Medication for Generalized Anxiety Disorder: Options, Benefits, and Risks.
Panic disorder
Panic attacks include an abrupt surge of intense fear or discomfort with multiple physical and cognitive symptoms. Because palpitations and tremor can be prominent, beta blockade may seem intuitively matched to the syndrome. Trials have not shown robust disorder-level benefit. The 2025 meta-analysis found no evidence of meaningful advantage over placebo or benzodiazepines in the included panic-disorder studies. Archer et al. (2025) For the broader medication evidence base, see Medication for Panic Disorder: Options, Benefits, and Risks.
Social anxiety disorder
Social anxiety disorder requires more than visible autonomic arousal. Fear of scrutiny, negative evaluation, anticipatory processing, avoidance, safety behavior, and post-event rumination can all matter. Beta blockers may reduce selected physical signs, especially in a circumscribed performance context, but the available trials do not establish them as routine treatment for the full disorder. NICE recommends individual disorder-specific CBT as the initial treatment for adults and, when a person prefers pharmacotherapy, recommends an SSRI such as escitalopram or sertraline. NICE CG159
For the medication boundary in this diagnosis, see Medication for Social Anxiety Disorder: Options, Benefits, and Risks, and for the full diagnostic overview see Social Anxiety Disorder: Symptoms, Causes, Diagnosis, and Treatment.
Specific phobia and situational fear
NIMH uses phobia and public speaking as examples when explaining short-term off-label beta-blocker use for intense physical anxiety symptoms. NIMH Mental Health Medications That should not be read as evidence that beta blockers erase a learned phobic fear or replace exposure-based treatment. A person can have a slower pulse while still expecting catastrophe, avoiding the feared stimulus, or leaving the situation early.
Why reducing the body can still feel psychologically useful
Physical arousal and threat interpretation can amplify each other. If a person interprets a pounding heart or shaking voice as proof that disaster is imminent, dampening that bodily signal may make the situation feel more manageable. This is one plausible reason beta blockers can feel disproportionately helpful to people whose fear is strongly organized around visible or disruptive bodily symptoms.
The reverse is also possible. If someone relies on medication as the only reason they believe they can enter a feared situation, the medication can become part of a safety strategy. That does not automatically make its use harmful; it means the psychological function of the behavior matters. In exposure-based treatment, clinicians often examine whether safety behaviors support approach and learning or prevent the person from discovering that feared outcomes are tolerable or less likely than expected.
Beta blockers do not diagnose anxiety
A rapid heartbeat, tremor, sweating, dizziness, weakness, shortness of breath, or chest discomfort can occur during anxiety, but these symptoms also occur in medical conditions and as effects of medications, substances, dehydration, endocrine changes, arrhythmias, respiratory disease, and other causes. Improvement after a beta blocker does not prove that the original symptom was caused by anxiety.
This is particularly important because beta blockers themselves change heart rate and blood pressure and can mask some physiologic warning signs. When physical symptoms are new, severe, changing, unexplained, or medically concerning, the appropriate question is not “Did a beta blocker calm it?” but “Has the symptom been adequately assessed?” See Anxiety Symptoms and Medical Differential Diagnosis for the broader differential framework.
Off-label use: what the term means
In the United States, anxiety is not among the labeled indications on the propranolol tablet label used here. NIMH explicitly describes beta blockers for short-term anxiety symptoms as off-label. NIMH Mental Health Medications Off-label prescribing means that a licensed clinician uses an approved medication for a purpose, population, dose, route, or context that is not included in the FDA-approved labeling. It does not mean the drug is unapproved or automatically inappropriate; it does mean the evidence and clinical rationale need to be judged for that specific use.
Safety: why propranolol is not a casual performance aid
A drug that changes heart rate, blood pressure, airway beta receptors, glucose warning signals, and interactions with other medicines requires medical context. The fact that a person intends to use propranolol only for a presentation does not erase its cardiovascular and respiratory pharmacology.
Heart rate, blood pressure, and conduction problems
The U.S. propranolol label lists cardiogenic shock, sinus bradycardia, greater-than-first-degree heart block, bronchial asthma, and hypersensitivity among contraindications. Reported cardiovascular adverse reactions include bradycardia, hypotension, worsening heart failure, and intensification of atrioventricular block. DailyMed propranolol label
Asthma and bronchospasm
Propranolol is nonselective and blocks beta-2 receptors as well as cardiac beta-1 receptors. Its U.S. label contraindicates use in bronchial asthma and warns that people with bronchospastic lung disease generally should not receive beta blockers because propranolol can interfere with beta-mediated bronchodilation. DailyMed propranolol label
This is one reason “I only want something for the shaking” is not enough information to decide whether a beta blocker is appropriate. Respiratory history matters, and different beta blockers have different receptor selectivity and indications.
Diabetes and low blood sugar
Beta blockade can make some warning signs of hypoglycemia—especially pulse and blood-pressure changes—less obvious. The propranolol label also reports hypoglycemia in several clinical contexts. NIMH advises particular caution with beta blockers in people with diabetes. DailyMed and NIMH
Dizziness, fatigue, sleep, and cognitive complaints
Dizziness and fatigue can matter even when the medication reduces anxiety-related tremor. A 2025 systematic review and meta-analysis of neuropsychiatric adverse events found an increased risk of dizziness with beta blockers versus placebo; lipophilic beta blockers, especially propranolol, showed a larger association in the included studies, and propranolol was also associated with a small increase in insomnia risk. Ez Eddin et al. (2025)
The official propranolol label also lists lightheadedness, weakness, fatigue, insomnia, vivid dreams, and other central nervous system effects among reported adverse events. DailyMed propranolol label
Medication and substance interactions
Propranolol interacts with multiple cardiovascular and other medications, and metabolism can be affected by drugs that influence CYP2D6, CYP1A2, or CYP2C19 pathways. MedlinePlus advises patients to tell clinicians and pharmacists about prescription drugs, nonprescription medicines, vitamins, supplements, and herbal products; it also notes that alcohol can increase the amount of propranolol in the body. MedlinePlus propranolol
Pregnancy, breastfeeding, surgery, and other medical conditions
MedlinePlus advises discussing pregnancy, plans for pregnancy, breastfeeding, surgery, kidney or liver disease, diabetes, heart disease, asthma or other lung disease, and other relevant conditions before propranolol use. MedlinePlus propranolol These considerations are reasons for clinician review, not a checklist for self-clearing a prescription.
Do not stop a chronically prescribed beta blocker abruptly
People sometimes encounter propranolol through an anxiety discussion and assume that because it may be used intermittently in some performance contexts, all beta-blocker use can be started and stopped casually. That inference is unsafe. The propranolol label warns that abrupt discontinuation after chronic therapy has been associated with worsening angina and, in some cases, myocardial infarction. DailyMed propranolol label
The rule is broader than anxiety: if a beta blocker has been prescribed regularly, changes should be discussed with the prescriber. This article does not provide a taper schedule because the appropriate plan depends on the drug, formulation, dose, duration, cardiovascular indication, and individual risk.
Beta blockers versus other anxiety treatments
The best treatment comparison depends on the diagnosis and the target. A medication that is useful for a short-lived tremor before public speaking answers a different clinical question from a treatment intended to reduce generalized worry, recurrent unexpected panic attacks, or persistent social avoidance.
Beta blockers versus CBT and exposure-based treatment
CBT can target interpretations, attentional patterns, avoidance, safety behavior, anticipatory processing, and behavioral learning. For social anxiety disorder, NICE recommends individual disorder-specific CBT as the initial treatment for adults. NICE CG159 A beta blocker may change physical arousal during a performance, but it does not reproduce the learning mechanisms of CBT or exposure.
Beta blockers versus SSRIs and SNRIs
SSRIs and SNRIs are used as disorder-level treatments for several anxiety disorders and typically require regular use over time rather than one-off situational dosing. NIMH notes that clinicians commonly start with SSRIs or other antidepressants for panic disorder or social anxiety disorder. NIMH Mental Health Medications Their benefits, adverse effects, onset, and discontinuation issues differ substantially from beta blockers.
Beta blockers versus benzodiazepines
Benzodiazepines act centrally and can rapidly reduce anxious feelings as well as physical arousal, but sedation, psychomotor impairment, tolerance, physical dependence, withdrawal, and misuse risk change their clinical role. Beta blockers do not share the same pharmacologic dependence profile, yet they have their own cardiovascular and respiratory risks and are not an evidence-equivalent substitute for benzodiazepines in anxiety disorders. In the limited comparative trials included in systematic reviews, propranolol did not show a reliable advantage over benzodiazepines for panic disorder. Archer et al. (2025)
Beta blockers versus buspirone
Buspirone is used differently: NIMH describes it as a medication that can be used for anxiety over longer periods and that must be taken regularly rather than as an as-needed treatment. NIMH Mental Health Medications The dedicated AXD-232 buspirone page is reserved in this cluster and will be linked here once it is live.
When might the beta-blocker question be clinically reasonable?
The question is most coherent when the target symptom and situation are specific: a predictable performance or evaluative event; prominent adrenergic symptoms such as tremor or racing heart; a medical history that does not create a contraindication; no unsafe medication interaction; and a clinician who has considered whether the person’s broader problem would be better treated by psychological therapy or a disorder-specific medication strategy.
The question is less coherent when the goal is to suppress all anxiety, when symptoms occur unpredictably throughout the day, when chronic worry or avoidance is the main impairment, when a person is trying to self-treat unexplained palpitations or shortness of breath, or when medical contraindications have not been assessed.
Questions worth discussing with a clinician
A useful medication conversation starts with the treatment target: Which symptom are we trying to change—tremor, tachycardia, panic, generalized worry, fear of evaluation, or avoidance? Is the anxiety brief and performance-linked or persistent across settings? Does the pattern meet criteria for an anxiety disorder? What heart rate, blood pressure, respiratory, metabolic, pregnancy, medication-interaction, or other medical factors matter? What evidence supports this medication for this particular diagnosis? What would count as benefit, what would count as an adverse effect, and what longer-term treatment addresses the underlying pattern if the problem is recurring?
These questions are more informative than asking whether beta blockers are simply “strong” or “weak.” They clarify what the medication can plausibly change and what remains untreated.
What beta blockers can and cannot be expected to change
Physical symptom reduction is not the same as anxiety-disorder remission
A lower heart rate or steadier hand is a measurable physiologic change. Remission from an anxiety disorder is a broader clinical outcome involving the disorder’s defining symptoms, functional impairment, avoidance, distress, and persistence over time. A treatment can improve one component without producing the other. This distinction is especially important when interpreting beta-blocker studies because some older trials measured somatic anxiety or short-term state anxiety, while modern clinical questions often concern sustained disorder-level recovery.
The 2025 systematic review found that even when anxiety symptom scales and panic outcomes were analyzed across the available controlled studies, there was no convincing benefit over placebo or benzodiazepines and confidence in the evidence was very low. Archer et al. (2025)
Feeling calmer is not the same as performing better
Performance anxiety research can ask at least three different questions: Does the person feel less anxious? Are physical signs such as tremor or tachycardia reduced? Does objective performance improve? Those outcomes can diverge. A musician may have a steadier hand without reporting much less fear; a speaker may feel less bodily activation without changing their belief that the audience is judging them; another person may feel calmer but perform no differently. Small historical studies cannot establish that beta blockers are general performance enhancers.
This is one reason the evidence should be described as symptom-specific rather than as proof that propranolol “treats stage fright” in every clinically meaningful sense. The 2019 systematic review of music performance anxiety found substantial methodological limitations across the treatment literature. Fernholz et al. (2019)
Short-term symptom control is not long-term fear learning
When anxiety is maintained by avoidance, threat beliefs, self-focused attention, reassurance seeking, or safety behavior, a medication that temporarily reduces autonomic arousal does not automatically change those processes. Long-term improvement may require repeated experiences that update predictions and reduce avoidance. This is why the same person might reasonably discuss both a situational symptom-control option and a psychological treatment plan if the fear is recurrent or impairing.
Where beta blockers are not established treatments
Beta blockers should not be turned into a catch-all treatment simply because many anxiety presentations share palpitations or tremor. Anxiety Disorders: Symptoms, Types, Diagnosis, and Treatment separates the recognized anxiety disorders because each has its own defining fear pattern, impairment criteria, differential diagnosis, and treatment evidence.
Agoraphobia centers on fear or avoidance of situations where escape or help may feel difficult. Separation anxiety disorder centers on excessive fear concerning separation from attachment figures. Selective mutism involves a persistent failure to speak in specific social situations despite speaking in others. A beta blocker may alter a physical sign that happens during any of these states, but there is no basis for treating that physiologic effect as evidence that the medication addresses the disorder’s core clinical mechanism.
Specific phobia also illustrates the difference. A person might experience intense tachycardia when facing a feared animal, procedure, height, or situation. Lowering the heart rate does not by itself extinguish the learned fear or eliminate avoidance. Exposure-based psychological treatment has a different purpose: changing the person’s relationship to the feared cue through corrective learning and repeated approach.
Children, adolescents, and older adults require separate judgment
Evidence from adult situational use should not be automatically extrapolated to children and adolescents. NICE recommends psychological treatment for social anxiety disorder in children and young people and advises against routinely offering pharmacological interventions for that disorder in this age group. NICE CG159
At the other end of the age range, dizziness, hypotension, bradycardia, polypharmacy, cardiovascular disease, and changes in drug clearance can become more clinically important. The propranolol label notes reduced clearance with aging and advises cautious dose selection in older patients because of the greater frequency of reduced organ function, concomitant disease, and other drug therapy. DailyMed propranolol label
These are not arguments for or against a beta blocker for a particular person. They show why the correct clinical unit is the individual patient, the specific beta blocker, the target symptom, the medical context, and the evidence for the diagnosis—not the generic idea that a medicine “works for anxiety.”
Frequently asked questions
Do beta blockers cure anxiety?
No. Beta blockers can reduce selected physical symptoms of short-term anxiety, but they do not remove the underlying capacity for fear or worry and are not established as curative treatment for anxiety disorders. The best current systematic review found no robust disorder-level benefit. Archer et al. (2025)
Which beta blocker is most often associated with anxiety treatment?
Propranolol is the best-known example in the anxiety literature. It is a nonselective beta blocker. Other beta blockers have been studied or used in some contexts, but the drugs are not clinically interchangeable and evidence for one should not be assumed to apply to all.
What anxiety symptoms do beta blockers help most?
The clearest target is adrenergic physical arousal: a rapid or pounding heartbeat and tremor, with some sources also noting sweating. They are much less directly matched to worry, fear of judgment, catastrophic thoughts, avoidance, or safety behavior. NIMH Social Anxiety Disorder
Are beta blockers FDA-approved for anxiety?
NIMH describes beta blockers used for short-term anxiety symptoms as off-label in the United States. NIMH Mental Health Medications Propranolol itself is an approved medication for other indications; “off-label” refers to the anxiety use, not to the legality or approval status of the drug itself.
Can propranolol help public speaking anxiety?
It can reduce physical arousal that interferes with a presentation, and authoritative sources recognize this performance-anxiety use. The evidence base is nevertheless much smaller and older than its popularity might suggest. Small stage-fright studies exist, while later reviews emphasize methodological limitations and a lack of strong modern trials. Brantigan et al. (1982); Fernholz et al. (2019)
Can beta blockers prevent panic attacks?
Current evidence does not support beta blockers as a reliable routine treatment for panic disorder. The 2025 meta-analysis found no evidence of benefit over placebo or benzodiazepines in the available panic-disorder trials. Archer et al. (2025)
Are beta blockers a good treatment for generalized anxiety disorder?
They are not established as a routine GAD treatment. GAD centers on persistent excessive worry and broader symptom patterns, and disorder-specific treatments have a stronger evidence base. A clinician may sometimes target a particular physical symptom, but that is different from treating GAD as a whole.
Are beta blockers addictive?
Beta blockers are not benzodiazepines and are not used for their sedative or euphoric effects. The major medication risks are different. However, a regularly prescribed beta blocker should not be stopped abruptly without medical guidance because sudden discontinuation can be medically hazardous in some people. DailyMed propranolol label
Can someone with asthma take propranolol for anxiety?
Bronchial asthma is listed as a contraindication in the U.S. propranolol label, and the label warns about bronchospasm in bronchospastic lung disease. DailyMed propranolol label A clinician must evaluate respiratory history and the specific drug rather than treating “beta blocker” as a single interchangeable category.
Can a beta blocker hide a medical problem by making the heart rate slower?
It can alter physiologic signs, which is one reason symptom response should not be used as a diagnostic test for anxiety. The propranolol label specifically notes that beta blockade can mask some warning signs of hypoglycemia and some clinical signs of hyperthyroidism. DailyMed propranolol label
How quickly does propranolol work for anxiety?
Oral propranolol is absorbed over hours, and the official label reports peak plasma concentrations roughly 1 to 4 hours after an oral dose, but onset of a desired effect depends on formulation, dose, food, metabolism, the symptom being targeted, and the individual. DailyMed propranolol label This is not a dosing or timing instruction; a prescriber or pharmacist should give person-specific guidance.
Can I use someone else’s propranolol before a presentation?
No. NIMH advises people not to take medication prescribed for another person. NIMH Mental Health Medications The relevant risks include heart rate and blood pressure effects, asthma or bronchospasm, diabetes-related masking of hypoglycemia, drug interactions, and individual contraindications.
What is the bottom line?
Beta blockers occupy a narrow but understandable place in anxiety treatment. Their strongest rationale is physical: they can dampen adrenergic signs that may disrupt a brief performance or evaluative situation. That can be meaningful for a person whose main impairment comes from tremor, palpitations, or visible autonomic arousal.
The larger claim—that beta blockers treat anxiety disorders broadly—is not supported by strong evidence. The 2025 systematic review found no robust benefit in the available social-anxiety and panic-disorder trials, and earlier reviews reached similar conclusions. For persistent social anxiety, panic disorder, generalized anxiety disorder, phobic avoidance, or recurrent impairment, treatment should be matched to the specific diagnosis and maintaining mechanisms rather than to the shared presence of a fast heartbeat.
The safest interpretation is also the most clinically useful: beta blockers can modify part of the anxiety response, not define the diagnosis and not replace a full treatment plan. For the cluster-wide clinical map, see Anxiety Disorders: Symptoms, Types, Diagnosis, and Treatment.
Related Articles
References
Archer, C., Wiles, N., Kessler, D., Turner, K., & Caldwell, D. M. (2025). Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 368, 90–99. https://doi.org/10.1016/j.jad.2024.09.068
Brantigan, C. O., Brantigan, T. A., & Joseph, N. (1982). Effect of beta blockade and beta stimulation on stage fright. American Journal of Medicine, 72(1), 88–94. https://doi.org/10.1016/0002-9343(82)90592-7
Ez Eddin, L., Preyra, R., Ahmadi, F., Jafari, A., Omrani, M. A., & Muanda, F. T. (2025). β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysis. British Journal of Clinical Pharmacology, 91(2), 325–337. https://doi.org/10.1111/bcp.16361
Fernholz, I., Mumm, J. L. M., Plag, J., Noeres, K., Rotter, G., Willich, S. N., Ströhle, A., Berghöfer, A., & Schmidt, A. (2019). Performance anxiety in professional musicians: A systematic review on prevalence, risk factors and clinical treatment effects. Psychological Medicine, 49(14), 2287–2306. https://doi.org/10.1017/S0033291719001910
MedlinePlus. (2026). Propranolol: Drug information. U.S. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a682607.html
National Institute for Health and Care Excellence. (2013, updated). Social anxiety disorder: Recognition, assessment and treatment (CG159). https://www.nice.org.uk/guidance/cg159/chapter/recommendations
National Institute of Mental Health. (2023). Mental health medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
National Institute of Mental Health. (2024). Social anxiety disorder: What you need to know. https://www.nimh.nih.gov/health/publications/social-anxiety-disorder-more-than-just-shyness
National Library of Medicine. (2025). DailyMed: Propranolol hydrochloride tablet—prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9288191e-4d07-4e37-ab66-7b9de9321cf3
Steenen, S. A., van Wijk, A. J., van der Heijden, G. J. M. G., van Westrhenen, R., de Lange, J., & de Jongh, A. (2016). Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 30(2), 128–139. https://doi.org/10.1177/0269881115612236
Vinther, S., Bøgevig, S., Petersen, T. S., Dalhoff, K. P., & Petersen, K. M. (2018). Limited evidence for effect and safety of propranolol for exam-related anxiety. Ugeskrift for Laeger, 180(50). https://pubmed.ncbi.nlm.nih.gov/30547878/